Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. has successfully closed a public offering of 2,631,578 shares of common stock at a price of $1.90 per share, raising total gross proceeds of $5 million, which will be used for working capital and general corporate purposes [1][3]. Group 1: Offering Details - The public offering included Series A-1 warrants and short-term Series A-2 warrants, both with an exercise price of $1.90 per share [2]. - The Series A-1 warrants are exercisable upon issuance and expire five years thereafter, while the Series A-2 warrants expire in 18 months [2]. - The potential additional gross proceeds from the Series A-2 warrants, if fully exercised, could amount to approximately $5 million [3]. Group 2: Company Background - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for infectious diseases and achieved FDA approval for its lead product, ARAKODA® (tafenoquine), in 2018 [6]. - The company collaborates with prominent research organizations in the U.S., Australia, and Singapore, and has received support from the U.S. Department of Defense and private institutional investors [6]. - The company is headquartered in Washington D.C. and has a majority-owned subsidiary in Australia [6].

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $5 million in gross proceeds, with potential additional proceeds of up to $5 million from short-term warrants [1][4]. Group 1: Offering Details - The public offering includes 2,631,578 shares of common stock or pre-funded warrants, along with Series A-1 and short-term Series A-2 warrants, priced at $1.90 per share [1][2]. - The Series A-1 warrants will have an exercise price of $1.90, exercisable upon issuance and expiring in five years, while the Series A-2 warrants will also have an exercise price of $1.90, expiring in 18 months [2]. - The closing of the offering is expected on or about July 16, 2025, pending customary closing conditions [2]. Group 2: Financial Implications - The gross proceeds from the offering are expected to be approximately $5 million before deducting fees and expenses, with an additional potential of $5 million from the exercise of Series A-2 warrants [4]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes [4]. Group 3: Company Background - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for infectious diseases, having achieved FDA approval for its lead product, ARAKODA, in 2018 [7]. - The company collaborates with prominent research organizations in the U.S., Australia, and Singapore, and has received support from the U.S. Department of Defense and private investors [7].

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in net product revenues and gross profit for Q1 2025, driven primarily by domestic sales of its lead product ARAKODA® [5][6]. Financial Highlights - Net product revenues for Q1 2025 increased by approximately 55% year-over-year, reaching about $163.6 thousand, up from $105.7 thousand in Q1 2024 [6]. - Gross profit for Q1 2025 was approximately $90.3 thousand, representing a 124% increase from approximately $40.2 thousand in Q1 2024 [5][6]. - Operating expenses rose to approximately $2.09 million in Q1 2025, compared to approximately $1.41 million in Q1 2024, with increased expenditures in sales and investor-related services contributing to this rise [6]. - The net loss attributable to common shareholders for Q1 2025 was approximately $2.01 million, or ($1.56) per share, contrasting with a net income of approximately $308.7 thousand, or $1.83 per share in Q1 2024 [6].